| Title |
Baloxavir: First Global Approval
|
|---|---|
| Published in |
Drugs, April 2018
|
| DOI | 10.1007/s40265-018-0899-1 |
| Pubmed ID | |
| Authors |
Young-A Heo |
| Abstract |
Baloxavir marboxil (Xofluza™; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 93 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 17% |
| Student > Master | 10 | 11% |
| Researcher | 9 | 10% |
| Student > Ph. D. Student | 8 | 9% |
| Student > Doctoral Student | 5 | 5% |
| Other | 13 | 14% |
| Unknown | 32 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 15 | 16% |
| Medicine and Dentistry | 15 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Agricultural and Biological Sciences | 5 | 5% |
| Chemistry | 4 | 4% |
| Other | 11 | 12% |
| Unknown | 33 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2024.
All research outputs
#3,314,097
of 25,605,018 outputs
Outputs from Drugs
#457
of 3,475 outputs
Outputs of similar age
#65,008
of 343,941 outputs
Outputs of similar age from Drugs
#12
of 28 outputs
Altmetric has tracked 25,605,018 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,475 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.